CoverageForm 410-K10-Q8-K13D13G13F

JYNT · Joint Corp - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Price · JYNT

Income Statement

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Revenue------$30.20M$30.26M$29.72M-
Cost of Revenue$2.72M-$2.66M$2.77M$2.97M-$2.82M$2.83M$2.72M-
Gross Profit------$27.38M$27.43M$27.01M-
R&D----------
SG&A$11.20M-$10.56M$11.63M$10.78M-$26.76M$29.50M$25.55M-
Total Operating Expenses----------
D&A$404.4K-$446.7K$402.3K$388.3K-$1.24M$1.52M$1.40M-
Operating Income$873.7K-$160.9K($1.14M)($678.5K)-($3.19M)($3.50M)$1.09M-
Interest Expense----------
Income Tax$11.1K-$10.3K$11.4K$13.4K-$62.6K$178.3K$178.9K-
Net Income$1.30M-$855.0K$93.4K$801.4K-($3.17M)($3.60M)$947.0K-
EPS - Basic$0.09-$0.06$0.01$0.05-($0.21)($0.24)$0.06-
EPS - Diluted$0.09-$0.06$0.01$0.05-($0.21)($0.24)$0.06-

Balance Sheet

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Cash & Equivalents$20.68M$23.60M$29.70M$29.81M$21.92M$25.05M$20.74M$17.46M$18.74M$18.15M
Accounts Receivable$2.34M$2.85M$2.90M$2.79M$2.97M$2.59M$4.30M$3.58M$3.27M$3.72M
Inventory----------
Accounts Payable$961.3K$1.59M$1.20M$1.58M$1.02M$1.75M-$1.64M$1.28M$1.63M
Current Assets$49.59M$52.09M$60.50M$63.75M$67.83M$72.19M$55.17M$43.39M$44.63M$44.34M
Total Assets$57.92M$60.97M$69.39M$73.18M$77.19M$80.42M$79.60M$82.44M$85.68M$87.15M
Current Liabilities$30.17M$32.82M$33.05M$35.51M$42.71M$49.35M$38.29M$34.01M$33.35M$33.57M
Long-term Debt----------
Total Liabilities$42.43M$45.89M$46.66M$49.92M$57.26M$62.48M$59.12M$59.23M$59.48M$62.38M
Stockholders' Equity$15.47M$15.05M$22.70M$23.24M$19.91M$17.92M$20.45M$23.19M$26.18M$24.75M
Retained Earnings($23.50M)($24.80M)($25.79M)($26.64M)($29.63M)($30.44M)($27.72M)($24.55M)($20.96M)($21.91M)

Cash Flow

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Operating Cash Flow($1.48M)---($3.70M)---$2.81M-
Investing Cash Flow($234.6K)---($291.4K)---($344.9K)-
Financing Cash Flow($1.16M)---$893.2K---($2.01M)-
CapEx$234.6K---$331.5K---$395.0K-
Free Cash Flow($1.71M)---($4.03M)---$2.42M-

Ratios

MetricQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Profitability
Gross margin------90.7%90.7%90.9%-
Operating margin-------10.5%-11.6%3.7%-
EBITDA margin-------6.4%-6.5%8.4%-
Net margin-------10.5%-11.9%3.2%-
Free cash flow margin--------8.1%-
FCF / Net income-1.32----5.03---2.55-
R&D / Revenue----------
SG&A / Revenue------88.6%97.5%86.0%-
Effective tax rate0.8%-1.2%10.9%1.6%---15.9%-
Return on assets2.2%-1.2%0.1%1.0%--4.0%-4.4%1.1%-
Return on equity8.4%-3.8%0.4%4.0%--15.5%-15.5%3.6%-
Return on invested capital----------
Liquidity
Current ratio1.641.591.831.801.591.461.441.281.341.32
Quick ratio1.641.591.831.801.591.461.441.281.341.32
Cash ratio0.690.720.900.840.510.510.540.510.560.54
Leverage
Debt / Equity----------
Debt / Assets----------
Debt / EBITDA----------
Interest coverage----------
Equity multiplier3.744.053.063.153.884.493.893.563.273.52
Liabilities / Assets0.730.750.670.680.740.780.740.720.690.72
Efficiency
Asset turnover------0.380.370.35-
Inventory turnover----------
Days sales outstanding------52d43d40d-
Days inventory outstanding----------
Days payable outstanding129d-165d208d126d--212d172d-
Cash conversion cycle----------
Valuation
P / E98.3x-159.0x1154.0x249.8x---217.7x-
P / B8.1x-6.5x7.6x9.6x-8.5x9.2x7.5x-
P / S------5.8x7.1x6.6x-
EV / EBITDA82.0x-192.9x-----71.1x-
Growth
Revenue growth (YoY)------2.5%3.3%4.5%-
Revenue CAGR (3y)------12.9%14.4%19.2%-
Revenue CAGR (5y)------18.9%22.1%22.7%-
Gross profit growth (YoY)------1.9%2.7%4.6%-
Operating income growth (YoY)---67.5%---254.8%-833.9%--
Net income growth (YoY)62.1%----15.4%--341.9%-1022.2%-58.8%-
EPS growth (YoY)80.0%----16.7%--320.0%-1100.0%-60.0%-
EPS CAGR (3y)-15.7%-26.0%-20.6%-----27.9%-
EPS CAGR (5y)-10.9%--11.4%0.0%-3.6%-----
FCF growth (YoY)57.6%--------49.9%-
FCF CAGR (5y)----------
Book value growth (YoY)-22.3%-16.0%11.0%0.2%-23.9%-27.6%-42.0%-34.6%-25.4%-23.6%

Sales by segment

From XBRL dimensional facts in the 10-K period ending 2023-12-31.

Business segments

$117.70M total
Corporate Clinics$70.72M · 60.1%
Franchise Operations$46.98M · 39.9%

Peer comparison

Same SIC group: Patent Owners & Lessors

CompanyRevenue (last FY)Net marginROE
IDCC$834.01M48.8%36.9%
APPS$565.25M-6.7%-19.6%
DLB$1.35B18.9%9.7%
ACTG$285.23M7.6%4.0%
FRG$4.40B-1.6%-16.3%

Comparing JOINT Corp against the 5 most active filers in the same SIC group.